Which medications in the drug class Antiplatelet Agents, Cardiovascular are used in the treatment of Metabolic Syndrome?

Updated: Mar 30, 2020
  • Author: Stanley S Wang, JD, MD, MPH; Chief Editor: Yasmine S Ali, MD, MSCI, FACC, FACP  more...
  • Print

Antiplatelet Agents, Cardiovascular

These agents inhibit platelet aggregation.

Aspirin (Ecotrin, Ascriptin, Bayer Aspirin, Buffinol)

Aspirin is an odorless, white, powdery substance available in 81mg, 325mg, and 500mg form for oral use. When exposed to moisture, aspirin hydrolyzes into salicylic acid and acetic acids.

Aspirin is a stronger inhibitor of prostaglandin synthesis and platelet aggregation than are other salicylic acid derivatives. The acetyl group is responsible for inactivation of cyclooxygenase via acetylation. Aspirin is hydrolyzed rapidly in plasma, and elimination follows zero order pharmacokinetics.

Aspirin irreversibly inhibits platelet aggregation by inhibiting platelet cyclooxygenase. This, in turn, inhibits conversion of arachidonic acid to prostaglandin I2 (potent vasodilator and inhibitor of platelet activation) and thromboxane A2 (potent vasoconstrictor and platelet aggregating agent). Platelet inhibition lasts for the life of the cell (approximately 10 days).

Aspirin may be used in low dose to inhibit platelet aggregation and improve complications of venous stases and thrombosis. It reduces the likelihood of myocardial infarction and is also very effective in reducing the risk of stroke. Early administration of aspirin in patients with acute myocardial infarction may reduce cardiac mortality in the first month.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!